Information Provided By: 
Fly News Breaks for May 13, 2019
BMRN
May 13, 2019 | 08:05 EDT
Jefferies analyst Eun Yang sees a favorable risk/reward on BioMarin shares following her physician poll on valrox. The analyst sees a "reasonable likelihood" that the three-year follow-up data, to be reported by June 7, will show durable efficacy and FVIII expression similar to that at year two. However, the stock's current valuation reflects little such expectation, Yang tells investors in a research note. She keeps a Buy rating on BioMarin with a $125 price target.
News For BMRN From the Last 2 Days
There are no results for your query BMRN
